Related Experiment Video
Updated: Jan 4, 2026
Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
Future developments in renal cell carcinoma
1Solid Tumor Oncology (Genitourinary and Gastrointestinal) Section, Medical Oncology Service, Hospital Del Mar, Barcelona, Spain. jbellmunt@imas.imim.es
Background:
The development of targeted agents has substantially improved prognoses for patients with metastatic renal cell carcinoma (mRCC). Four targeted agents are approved for the treatment of mRCC in Europe (bevacizumab given in combination with interferon-alfa, sorafenib, sunitinib and temsirolimus) and a number of investigational agents have shown potential in this setting.
Design:
This report will review completed and ongoing clinical trials in mRCC designed to investigate the efficacy of targeted agents in sequential and combination therapies and in the adjuvant and neoadjuvant settings.
Results:
A phase III trial, in which 71% of patients received prior sunitinib treatment, has indicated that everolimus can be used after sunitinib, the reference standard of care for first-line therapy, to extend progression-free survival. Phase I/II studies have provided preliminary data on the efficacy of sequential and combination therapies with targeted agents in mRCC. Several phase III studies investigating targeted agents in sequential and combination therapies and in the adjuvant and neoadjuvant settings are planned or ongoing, and data are awaited with interest.
Conclusions:
Data suggest that sequential and combination therapies with targeted agents have potential in patients with mRCC. Ongoing research will help to optimise the use of targeted therapies in this setting.
Insights
Targeted therapies improve outcomes for metastatic renal cell carcinoma (mRCC). Everolimus shows efficacy after sunitinib, and ongoing trials explore sequential and combination treatments for advanced kidney cancer.
Area of Science:
- Oncology
- Pharmacology
Background:
- Metastatic renal cell carcinoma (mRCC) treatment has advanced with targeted agents.
- Four targeted agents are approved in Europe; investigational agents show promise.
Purpose of the Study:
- Review clinical trials investigating targeted agents in mRCC.
- Evaluate efficacy in sequential, combination, adjuvant, and neoadjuvant settings.
Main Methods:
- Review of completed and ongoing clinical trials in mRCC.
- Analysis of data on targeted agent efficacy.
Main Results:
- Everolimus demonstrated efficacy post-sunitinib, extending progression-free survival.
- Phase I/II studies show preliminary efficacy for sequential and combination therapies.
- Several Phase III studies are ongoing or planned.
Conclusions:
- Sequential and combination targeted therapies show potential for mRCC patients.
- Further research is needed to optimize targeted therapy use in mRCC.
More Related Videos
Related Concept Videos
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...